Results 191 to 200 of about 28,679 (286)

Lipid metabolic dysregulation in diabetic kidney disease: mechanisms, cellular impact, and therapeutic strategies. [PDF]

J Clin Transl Endocrinol
Wang Y, Wu L, Bao X, Yang J, Xu M, Chang Y, Liu Z, Qin L, Gao M, Lv C, Liu T.   +10 more
europepmc   +1 more source

Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application

MedComm, Volume 7, Issue 6, June 2026.
The modulation of the TME by fatty acid metabolism primarily occurs through four key pathways: inflammation regulation, signal transduction, translation to TME, and oxidative stress. ABSTRACT Fatty acid metabolism (FAM) plays a vital role in maintaining health by supporting energy production, cellular structure, and signaling processes.
Na Hang, Runkang Zhao, Fan Zhang, Dandan Guo, Qing Li, Zhijun Shen, Ruiqing Gao, Chenyu Gao, Zhao Xie, Sentao Fu, Peng Luo, Bufu Tang, Ling Wang   +12 more
wiley   +1 more source

Ectopic lipid deposition in kidney diseases: mechanisms in specific cell types and therapeutic strategies. [PDF]

Front Endocrinol (Lausanne)
Zhong Q, Zhang Y, Sun D, Peng J, Zhang P, Wang R, Cao L, Chen H, Wu C, He Z.   +9 more
europepmc   +1 more source

The Role of N6‐Methyladenosine Modification in Health and Disease

MedComm, Volume 7, Issue 6, June 2026.
N6‐methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotes, acting as a pivotal epitranscriptomic regulator of RNA metabolism. This modification plays a dual role: it maintains physiological homeostasis under normal conditions but drives disease progression when dysregulated.
Linghuan Li, Yuanhai Sun, Wanfang Zheng, Lingqin Li, Yaqian Feng, Minyou Qi, Hanbing Li   +6 more
wiley   +1 more source

CXCL6 exacerbates metabolic dysfunction-associated steatohepatitis by suppressing LPIN1-mediated fatty acid oxidation in hepatocytes. [PDF]

Int J Biol Sci
Cho YE, Kim MJ, Kim Y, Lim H, Park Y, Kim S, Kim SJ, Yoo JW, Ryu S, Song P, Hong C, He Y, Lee H, Cho JY, Hwang S.   +14 more
europepmc   +1 more source

Targeting Mitochondria in Aging‐Related Diseases: Therapeutic Potential and Obstacles

MedComm, Volume 7, Issue 6, June 2026.
This article systematically summarized the specific mechanism of aging‐related diseases caused by mitochondrial dysfunction, and summarized the broad‐spectrum treatment methods and disease targeted treatment strategies for mitochondria. At the same time, it also pointed out the dilemma faced by mitochondrial targeted treatment.
Zijie Xiang, Yu Chen, Xishui Liu, Haowen Lu, Yuqing Yang, Lei Xing, Yu Zhang, Chuandong Lang, Siming Zhang, Shixiang Zhao, Youzhi Hong, Jiaxiang Bai, Yusen Qiao   +12 more
wiley   +1 more source

The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Int J Mol Sci
Kotlyarova A, Iskrina A, Kotlyarov S.
europepmc   +1 more source

Stearoyl‐CoA Desaturase‐1 Drives Tumor Growth by Interacting With Histone Deacetylase‐2 and Deacetylating Nucleophosmin‐1

MedComm, Volume 7, Issue 6, June 2026.
Hypoxia induces SCD1 and PLIN2 to drive lipid droplet‐dependent metabolic adaptation in cancer cells. PLIN2 supports survival under stress, whereas SCD1 promotes proliferation upon reoxygenation and remodels the acetylome via HDAC2‐mediated NPM1 deacetylation and destabilization.
Coline Wery, Laetitia Montero‐Ruiz, Eric Bonneil, Mohammad Farran, Robin Jehay, Quentin Herrara Garfia, Gregory Fettweis, Silvia Blacher, Charles Pottier, Gael Cobraiville, Yasmine Boumahd, Olivier Peulen, Agnès Noël, Franck Dequiedt, Marianne Fillet, Nor Eddine Sounni   +15 more
wiley   +1 more source

Pathogenesis of diabetic cardiomyopathy and emerging therapeutic strategies: a network-based perspective. [PDF]

Front Clin Diabetes Healthc
Ren H, Lai H.
europepmc   +1 more source

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

Med Research, Volume 2, Issue 2, Page 309-342, June 2026.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source